| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 3 interim results example | VT-1953 Malignant Fungating Wounds (MFW) | Phase 3 | — | Small Molecules | Oncology | ||
Phase 3 interim results example | VT-1953 Malignant Fungating Wounds (MFW) | Phase 3 | — | Small Molecules | Oncology | ||
Phase 3 interim results example | VT-1953 Malignant Fungating Wounds (MFW) | Phase 3 | — | Small Molecules | Oncology |
Recent Updates
Recently added Catalysts
Vyome Holdings, Inc.$2.17
-0.01 (-0.46%)
F 2Pipeline Score Pharma · Commercial
Market Cap
15.65 M
EPS
-12.41
P/E Ratio
-
Value Trade
115.25 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
31.59 K
R&D Expenses
666.40 K
Operating CF
-1.44 M
Total Assets
10.19 M
Total Liabilities
2.14 M
Equity
8.04 M
D/E Ratio
12,345
15.54 %
Week
0 %
1 Month
-18.32 %
3 Month
-53.54 %
6 Month
-100 %
5 Year
-100 %
All Time
Cash Data
Cash Position
8.80 M
Monthly Burn
479.00 K
Runway
17.2 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
26.37 K
52 Week Range
1.75 - 33.16
% held by Insiders
52.82 %
% held by Institutions
1.48 %
Enterprise Value
8.18 M
Total Shares
7.00 M
Short %
2.35 %
Float Shares
1.79 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F2
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 4%
Micro Cap (rank 870 of 905)
Percentile RankVyome Holdings, Inc. has significant pipeline risk (2/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VT-1953 | malignant fungating wounds | Phase 2 | 2025-09-05 | |||
VT-1953 | malignant fungating wounds | Phase 2 | 2025-09-05 | |||
VT-1953 | malignant fungating wounds | Phase 2 | 2025-09-05 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in HIND
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
HIND
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HIND
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HIND
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
HIND Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
HIND Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
HINDVyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Holdings has reported its financial results for the first quarter of 2026, highlighting key FDA filings and a robust balance sheet. The report indicates the company's ongoing efforts to strengthen its position in the biopharma sector. Further details on the specific FDA filings and financial metrics were not disclosed in the article.
Read more →HINDVyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Vyome Pharmaceuticals has entered into a strategic partnership with Impetis Biosciences. This collaboration aims to explore opportunities in a market estimated to be worth approximately $57 billion. The deal is expected to enhance Vyome's position in the biopharma sector, although specific details about the partnership's terms have not been disclosed.
Read more →HINDVyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Vyome is set to present Phase 2 clinical data on VT-1953 for the treatment of MFW at the AACR 2026 conference. This presentation highlights the company's ongoing research efforts in this area. Details regarding the specific findings or implications of the data have not been disclosed.
Read more →HINDLivechain Completes Acquisition of Senior, Secured Debt of Humanyze, An MIT Incubated, AI Enabled HR Analytics Company
Livechain, a subsidiary of Vyome Holdings, has acquired Humanyze, an AI-enabled HR analytics company, through a debt purchase agreement. This all-stock transaction, valued at approximately $325,000, allows Livechain to take control of Humanyze's operations and assets. The acquisition aims to enhance Livechain's position in the AI HR sector and potentially lead to an uplisting on a national exchange.
Read more →HINDVyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Vyome Holdings, Inc. announced positive preclinical results for VT-1908, a potential treatment for uveitis, published in the Journal of Ophthalmic Inflammation and Infection. The study demonstrated that VT-1908 effectively reduced uveitis scores without toxicity, positioning it as a viable alternative to traditional steroids. The company aims to advance VT-1908 into clinical development, targeting a significant market opportunity.
Read more →HINDVyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Holdings has filed for Orphan Drug Status for its lead program VT-1953, which targets malignant fungating wounds (MFW) affecting advanced cancer patients. The company reported positive Phase 2 results and anticipates significant market potential, with a projected U.S. asset value of $455 million. Vyome aims to advance this program strategically over the next six months.
Read more →HINDVyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Vyome Holdings has successfully secured funding for its VT-1953 Phase 3 study, ensuring capital for interim results expected in mid-2027. The company utilized its At-The-Market facility, achieving this with minimal dilution. Management emphasized their commitment to shareholder value and noted the drug's potential worth of $1 billion upon trial completion.
Read more →HINDIndependent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome Holdings announced a valuation analysis for its lead candidate VT-1953, aimed at treating malignant fungating wounds. Conducted by Destum Partners, the assessment suggests a potential market value of USD 1 billion following successful Phase 3 trials. The analysis highlights a significant unmet need in oncology supportive care, with estimated peak sales of USD 600 million.
Read more →HINDVyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Vyome Holdings' subsidiary, LiveChain, has signed a letter of intent to acquire a senior secured note from Humanyze, an AI-driven HR analytics company. The deal, valued at approximately $325,000 in stock, positions LiveChain as Humanyze's senior secured creditor. This acquisition aims to enhance LiveChain's financial independence and create value for shareholders, although the transaction is subject to final agreements.
Read more →Competitive Position
How HIND ranks across every disease it competes inCompetitive Position is a premium feature
See how HIND ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial